Testosterone therapy in the new era of Food and Drug Administration oversight

The Food and Drug Administration (FDA) introduced changes in labeling and indications for use to testosterone products in 2015 due to a possible increased risk of cardiovascular (CV) events. This decision was made based on six clinical studies—some that supported an increased CV risk, and some that...

Descripción completa

Detalles Bibliográficos
Autores principales: Desroches, Bethany, Kohn, Taylor P., Welliver, Charles, Pastuszak, Alexander W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837303/
https://www.ncbi.nlm.nih.gov/pubmed/27141448
http://dx.doi.org/10.21037/tau.2016.03.13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837303/
https://www.ncbi.nlm.nih.gov/pubmed/27141448
http://dx.doi.org/10.21037/tau.2016.03.13

Ejemplares similares